Cancer Research

Papers
(The H4-Index of Cancer Research is 62. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Abstract P1-13-04: Evaluation of the impact Vitamin D and Calcium supplementation on bone mineral density in breast cancer patients using or not taking Aromatase Inhibitors: 5-year follow-up507
Abstract P4-12-09: Implications of protocol modifications and treatment delays for breast cancer patient experiences during Covid-19204
Abstract P2-12-23: Changes in 18F-FDG-PET uptake after the first course of DTX reflect response to preoperative chemotherapy and prognosis in breast cancer185
Abstract OT1-05-01: Glycoprotein 88 (GP-88) serum levels as a marker of response to therapy in patients with metastatic breast cancer162
Abstract P3-19-16: Impact of targeted intraoperative (TARGIT-IORT) tumor bed boost during breast conserving surgery for early breast cancer on breast cancer associated and non-breast cancer associated161
Abstract PD13-07: Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative l153
Abstract P3-20-09: Surgery vs radiation therapy as the first stage treatment in patients with locally advanced breast cancer with incomplete clinical response144
Abstract P5-08-02: MORAb-202, an antibody-drug-conjugate (ADC) targeting folate receptor alpha (FRα), exhibits durable anti-tumor efficacy in PDx models of TNBC138
Abstract P3-12-20: Outcomes of patients with pathologic complete response following neoadjuvant HER2-targeted therapy in patients with HER2+ early stage breast cancer132
Abstract P4-01-16: Overcome chemoresistance of triple-negative breast cancer by inhibiting the RNA-binding protein HuR131
Abstract PD3-03: EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression125
Abstract OT2-21-01: A randomized, multicenter pragmatic trial comparing bone pain from a single dose of pegfilgrastim to 5 doses of daily filgrastim in breast cancer patients receiving neoadjuvant/adj121
Abstract P4-11-16: Feasibility and patient satisfaction with a smartphone application to improve medication adherence among patients with breast cancer120
Abstract P3-18-14: Assessment of quality of life and objective cosmetic outcome of breast conserving surgery with or without latissimus dorsi mini-flap in breast cancer119
Abstract P4-05-09: Clinicopathologic characteristics and molecular profiling of HER2-low breast cancer: A single academic institution experience119
Abstract P1-08-09: High mid-treatment RNA disruption in patients with HER2-negative breast cancer predicts survival benefit after neoadjuvant chemotherapy117
Abstract P1-07-01: Real time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: Feasibility and cross-validation with NGS112
Abstract P4-11-05: How to stay sexually active and sexually well-functioning after breast cancer - Reporting from the SWEET study111
Abstract P1-06-01: Insights from rapid autopsy shed light on mechanisms of cancer dissemination in metastatic breast cancer109
Abstract P1-08-07: Prediction model of the response of neoadjuvant chemotherapy and long term survival according to multi-omic profiling in cooperation with clinicopathologic features in patients with109
Abstract ES8-2: Can radiation replace ALND after positive SLNB?106
Abstract P5-14-10: Examining inequities associated with incarceration among patients with breast cancer101
Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2− breast98
Abstract P5-13-17: PD-L1 expression in breast to brain metastases95
Abstract PD4-03: Characterization of HER2 amplification in the cerebrospinal fluid of patients with Leptomeningeal Disease in stage IV patients with breast cancer95
Abstract P2-15-01: Conversion from luminal to normal intrinsic subtype by PAM50 after neoadjuvant endocrine therapy is associate with biomarkers of good prognosis in luminal breast cancer91
Abstract PO-119: DFMO mediated improvement in survival of an orthotopic model of pancreatic cancer is associated with modulating immune suppression in the tumor microenvironment89
Editor's Note: p38 Mitogen-Activated Protein Kinase-Driven MAPKAPK2 Regulates Invasion of Bladder Cancer by Modulation of MMP-2 and MMP-9 Activity88
Abstract P1-18-17: Phase I study of cfi-402257, an oral ttk inhibitor, in patients with advanced solid tumors with breast cancer expansion cohorts84
Hyperactive Dendritc Cells Redirect Aged Antitumor Immunity84
Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma80
Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors79
Polypharmacologic Reprogramming of Tumor-Associated Macrophages toward an Inflammatory Phenotype78
Abstract P5-13-12: Immune signatures and MammaPrint (ultra) high risk class (MP2) as predictors of response to pembrolizumab combined with the TLR9 agonist SD101 in the neoadjuvant I-SPY 2 TRIAL78
Abstract P5-01-03: Mouse-intraductal (MIND): An in vivo model for studying the underlying mechanisms of DCIS malignancy78
Abstract 7218: Preventive use of trilaciclib in Chinese patient with extensive-stage small cell lung cancer (ES-SCLC) receiving chemotherapy: A multi-center, single-arm, observational real-world study77
Bcl-xL Enforces a Slow-Cycling State Necessary for Survival in the Nutrient-Deprived Microenvironment of Pancreatic Cancer77
Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity76
SMARCA4 Inhibits Breast Cancer Progression and Metastasis through RHOA Suppression76
A Genetic Locus within the FMN1/GREM1 Gene Region Interacts with Body Mass Index in Colorectal Cancer Risk74
Abstract 2074: MALDI-ICC: a new tool for high-plex, multiomic profiling of single cells for cancer research and cancer therapy73
A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants73
Abstract CT035: Pharmacokinetics (PK), safety, and tolerability of pembrolizumab with berahyaluronidase alfa administered subcutaneously Q3W in participants with advanced melanoma73
Abstract 4686: Efficacy and safety of efbemalenograstim alfa as primary prophylaxisfor concurrent chemo-radiotherapy induced neutropenia73
Abstract 3731: The role of dietary patterns and microbiome composition in colorectal cancer survival: The ColoCare Study72
Abstract 3727: Physical activity patters according to demographic, social, and clinical correlates among breast cancer survivors72
Abstract 1913: Cystic fluid acetylated polyamines predict risk of malignancy of intraductal papillary mucinous neoplasms of the pancreas71
Abstract 3371: Gene deletions in estrogen receptor positive HER2-negative breast cancer are associated with worse outcome than predicted by diagnostic-grade gene expression assays70
Abstract 1320: Nanotopographical cues enhance glioblastoma migration: Harnessing biomimetic matrices and machine learning to uncover cancer invasion70
Abstract 3688: Correlation between natural killer cell sensitivity and epithelial mesenchymal transition morphology: A cell morphology based screening for NK cell susceptible tumor cells70
Abstract 1273: Advancing precision oncology: Development and utilization of breast cancer PDX models for in vivo drug discovery70
Abstract 1124: Mining the Kras-p53 mutational interface for synthetic lethality (SL) in pancreatic adenocarcinoma (PA)69
Abstract 294: TFEB nuclear persistence predicts sensitivity to lysosomal inhibition in therapy-induced senescent thyroid cancer cells69
Abstract 3655: Leveraging alternative AIML technologies to identify predictive biomarkers for chemotherapy selection: An analysis of the COMPASS trial evaluating chemotherapy response in advanced PDAC66
Abstract 424: Chromosomal instability leads to EGFR-TKI refractoriness via cGAS-STING activation in EGFR-mutated non-small cell lung cancer65
Abstract 1510: Glutathione-oxidation of ovarian tumor deubiquitinase-1 promotes lung adenocarcinoma survival through stabilizing system xc-65
Abstract 2873: Preclinical development of SMP-656: An eribulin-SuperHydraTM linker based ADC65
Abstract 47: Optimizing in vivo establishment of hormone receptor-positive breast cancer patient-derived xenografts for therapeutic assessment65
Abstract 7085: Analysis of gene expression pattern of glycosphingolipid synthases using tumor tissues from breast cancer patients to identify key targets for early diagnosis and protection of recurren64
Abstract 679: Orthogonal confirmation using the Pacbio®two step universal adapter amplicon protocol to validate a comprehensive genomic profiling assay for hematologic malignancies64
Abstract 1120: Baseline biomarker analyses of patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC) from the phase 3 CodeBreaK 300 study64
Abstract 7210: Predicting drug response heterogeneity in AML: novel AI-enabled proteomics model for a prospective clinical trial63
Abstract 524: An integrative approach to unveiling biomarkers and therapeutic targets identifies novel treatment strategy for advanced prostate cancer62
Abstract 352: Preclinical development of MHB042C: A next-generation anti-c-Met ADC conjugating VHH-Fc fusion protein with a novel topoisomerase I inhibitor62
Abstract 7502: Radiation-induced transcriptomic reprogramming of mesenchymal glioblastoma stem cells reveals key pathways and potential targets62
0.2170250415802